RNAi agents for anaplastic thyroid cancer (Brigham & Women's Hospital/Massachusetts General Hospital)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameRNAi agents for anaplastic thyroid cancer (Brigham & Women's Hospital/Massachusetts General Hospital)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionRNA interference
TargetsUpdating
Therapy Area/IndicationsThyroid Carcinoma, Anaplastic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe Brigham and Women's Hospital
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe General Hospital Corporation D/B/A Massachusetts General HospitalThe Brigham and Women's Hospital
Active IndicationsN/A
Inactive IndicationsThyroid Carcinoma, Anaplastic

Other Information

ATC CodeN/A
Related LinksN/A